{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:11:55Z","timestamp":1777417915135,"version":"3.51.4"},"reference-count":35,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2003,1,1]],"date-time":"2003-01-01T00:00:00Z","timestamp":1041379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2003,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>To report a patient developing fulminant liver failure while being treated with clarithromycin for pneumonia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CASE SUMMARY<\/jats:title>\n                    <jats:p>A 58-year-old white woman developed fulminant liver failure while being treated with the macrolide antibiotic clarithromycin for pneumonia. Comedication included N-acetylcysteine, atenolol, and isradipine. Other causes of liver failure, such as viral hepatitis, autoimmune hepatitis, toxins, and heart failure, were excluded by appropriate diagnostic means. All drugs were stopped, and the patient was transferred to another hospital for liver transplantation. She recovered spontaneously within several days, making transplantation unnecessary. A liver biopsy obtained 10 days after the initial presentation revealed centroacinar necrosis and beginning fibrous reorganization, compatible with recent centroacinar damage.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DISCUSSION<\/jats:title>\n                    <jats:p>Since no other cause could be identified, liver injury was considered to be drug related. Fulminant liver failure has not previously been described with concomitant use of atenolol and N-acetylcysteine. Although isradipine has been associated with hepatocellular injury, there are no reports of fulminant liver failure with this agent, and our patient had been treated for &gt;2 years without signs of toxicity. The most likely cause of liver failure in this patient was, therefore, clarithromycin, which undergoes hepatic metabolism and has been reported to cause fulminant hepatic failure. A second possibility is an interaction between clarithromycin and isradipine, potentially increasing the hepatic toxicity of isradipine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>Clarithromycin may be a cause of fulminant liver failure either alone or by inhibiting the metabolism of other drugs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1345\/aph.1c171","type":"journal-article","created":{"date-parts":[[2003,6,4]],"date-time":"2003-06-04T16:28:03Z","timestamp":1054744083000},"page":"57-60","source":"Crossref","is-referenced-by-count":20,"title":["Fulminant Liver Failure Associated with Clarithromycin"],"prefix":"10.1177","volume":"37","author":[{"given":"Andreas","family":"Tietz","sequence":"first","affiliation":[{"name":"Andreas Tietz MD, Chief Resident, Department of Internal Medicine, University Hospital, Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus H","family":"Heim","sequence":"additional","affiliation":[{"name":"Markus H Heim MD, Head, Hepatology Unit, Division of Gastroenterology, University Hospital, Basel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Urs","family":"Eriksson","sequence":"additional","affiliation":[{"name":"Urs Eriksson MD, Resident, Division of Intensive Care, University Hospital, Basel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Marsch","sequence":"additional","affiliation":[{"name":"Stephan Marsch MD, Head, Division of Intensive Care, University Hospital, Basel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Terracciano","sequence":"additional","affiliation":[{"name":"Luigi Terracciano MD, Head, Liver Pathology Unit, Department of Pathology, University Hospital, Basel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Kr\u00e4henb\u00fchl","sequence":"additional","affiliation":[{"name":"Stephan Kr\u00e4henb\u00fchl MD PhD, Head, Division of Clinical Pharmacology & Toxicology, University Hospital, Basel"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2003,1,1]]},"reference":[{"key":"bibr1-aph.1C171","doi-asserted-by":"publisher","DOI":"10.1002\/lt.500050102"},{"key":"bibr2-aph.1C171","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)90171-X"},{"key":"bibr3-aph.1C171","first-page":"294","volume-title":"Liver disease. Diagnosis and management","author":"Kr\u00e4henb\u00fchl S","year":"2000"},{"key":"bibr4-aph.1C171","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1990.00390130175030"},{"key":"bibr5-aph.1C171","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-119-7_Part_1-199310010-00005"},{"key":"bibr6-aph.1C171","first-page":"394","volume":"91","author":"Shaheen N","year":"1996","journal-title":"Am J Gastroenterol"},{"key":"bibr7-aph.1C171","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.162.4.474"},{"key":"bibr8-aph.1C171","first-page":"489","volume":"97","author":"Christopher K","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"bibr9-aph.1C171","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/20.4.1074"},{"key":"bibr10-aph.1C171","first-page":"1034","volume":"20","author":"Cadranel JF","year":"1996","journal-title":"Gastroenterol Clin Biol"},{"key":"bibr11-aph.1C171","doi-asserted-by":"publisher","DOI":"10.1086\/313475"},{"key":"bibr12-aph.1C171","doi-asserted-by":"publisher","DOI":"10.1016\/0732-8893(93)90112-K"},{"key":"bibr13-aph.1C171","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/18.6.1025"},{"key":"bibr14-aph.1C171","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/20.4.1073"},{"key":"bibr15-aph.1C171","first-page":"632","volume":"21","author":"Sousa C","year":"1997","journal-title":"Gastroenterol Clin Biol"},{"key":"bibr16-aph.1C171","doi-asserted-by":"publisher","DOI":"10.1177\/00970002042006011"},{"key":"bibr17-aph.1C171","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"bibr18-aph.1C171","first-page":"1069","volume-title":"The pharmacological basis of therapeutics","author":"Tracy JW","year":"2001","edition":"10"},{"key":"bibr19-aph.1C171","first-page":"589","volume-title":"Hepatotoxicity","author":"Zimmerman HJ","year":"1999","edition":"2"},{"key":"bibr20-aph.1C171","unstructured":"20.  The Uppsala Monitoring Centre [cited 2002 Nov 7]. Available from: URL:http:\/\/www.who-umc.org."},{"key":"bibr21-aph.1C171","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-3003.2000.16b12.x"},{"key":"bibr22-aph.1C171","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198812153192401"},{"key":"bibr23-aph.1C171","doi-asserted-by":"publisher","DOI":"10.1542\/peds.79.2.281"},{"key":"bibr24-aph.1C171","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)91255-X"},{"key":"bibr25-aph.1C171","first-page":"1084","volume":"84","author":"Schwartz MS","year":"1989","journal-title":"Am J Gastroenterol"},{"key":"bibr26-aph.1C171","first-page":"623","volume":"25","author":"Rodrigues AD","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"bibr27-aph.1C171","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(98)90146-1"},{"key":"bibr28-aph.1C171","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199308050-00003"},{"key":"bibr29-aph.1C171","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(94)80249-1"},{"key":"bibr30-aph.1C171","first-page":"317","volume":"13","author":"Dubois A","year":"1989","journal-title":"Gastroenterol Clin Biol"},{"key":"bibr31-aph.1C171","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)90125-Z"},{"key":"bibr32-aph.1C171","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(83)90178-8"},{"key":"bibr33-aph.1C171","first-page":"685","volume":"224","author":"Pessayre D","year":"1983","journal-title":"J Pharmacol Exp Ther"},{"key":"bibr34-aph.1C171","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840130622"},{"key":"bibr35-aph.1C171","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199549040-00009"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1C171","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1345\/aph.1C171","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1C171","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:06:06Z","timestamp":1777374366000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.1C171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2003,1]]}},"alternative-id":["10.1345\/aph.1C171"],"URL":"https:\/\/doi.org\/10.1345\/aph.1c171","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,1]]}}}